HIPEC (Hyperthermic IntraPEritoneal Chemotherapy)

Novel, FDA-approved treatment for recurrent gynecologic cancer, in which all visible tumor is resected and the abdominal cavity is perfused with heated chemotherapy to enhance tumor kill and chemotherapy effect. We have provided HIPEC services under clinical trial setting since 2006, and were the first in the state of California.

Please see www.hipectreatment.com and HIPECClinicalTrials.gov for more details.

HEATT™ (Hyperthermia Extracorporeal Applied Tumor Therapy)

Proprietary, FDA-phase 1 experimental therapy for secondarily recurrent gynecologic cancer, in which the entire body is systemically heated to 42C   and detoxified to effect tumor kill.

PHASE I completed. Trial currently closed.

CFILM: A Randomized, Prospective, Open Label, Multicenter Study

Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Subjects with Uterine and Cervical Malignancies who are Undergoing Lymph Node Mapping: A collaborative international trial including MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Duke University, HIMA Puerto Rica, L’Hôtel-Dieu de Québec, and Sunnybrook Health Science Centre.

Trial currently closed.

Please see ClinicalTrials.gov for more details.

VOCAL: InterVenn Ovarian Cancer Liquid Biopsy

We are a study site for InterVenn Ovarian Cancer Liquid Biopsy (VOCAL). Venn Biosciences Corporation (“InterVenn”) has developed a liquid biopsy that is capable of distinguishing benign from malignant masses in women presenting with adnexal (pelvic) masses, through a simple blood test. The underlying technology combines mass spectrometry and artificial intelligence/machine learning to analyze tumor-associated changes in circulating glycoproteins. The purpose of this study is to prospectively collect de-identified biological samples and data from women with a known pelvic mass, to validate ovarian cancer specific glycoproteomic signatures in the blood based on histologically confirmed malignancy status of the mass.

Please see InterVenn.com and ClinicalTrials.gov for more details.